Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of H1N1 Vaccines GSK2340274A and GSK2340273A in Adults
NCT00979602Phase 3Completed
- Sponsor
- GSK
- Start
- Nov 2009
- Primary completion
- Jan 2011
- Modality
- Live Attenuated Vaccines, Whole Inactivated Vaccines
- Countries
- 2
01
Overview
Phase 3, randomised trial of Influenza A (H1N1) vaccine in influenza (2 arms), sponsored by GSK. Primary endpoints: Number of Seroconverted (SCR) Subjects for Hemagglutination Inhibition (HI) Antibodies Against Flu A/CAL/7/09 H1N1 Virus Strain at Day 182, Number of Seroprotected (SPR) Subjects for HI Antibodies Against the Flu A/CAL/7/09 H1N1 Virus Strain at Day 182 and 2 more. Started Nov 2009; status: completed.
02
Drugs
Influenza A (H1N1) vaccine
03
Conditions
influenza
Beyond the preview
Go deeper on NCT00979602.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00979602.